Rice University's Jones School of Business ranked No. 2 in Texas and No. 24 overall. Photo courtesy of Rice University

The 2023 results are in, and U.S. News and World Report has deemed three Houston universities among the best grad schools in the state, with some of its departments landing among the top 70 in the country.

Rice University's Jones School of Business ranked No. 2 in Texas and No. 24 overall in the nation, while the Brown School of Engineering earned the No. 30 spot among engineering schools, and third best program in Texas. Additionally, the university's department of psychology landed the No. 1 spot for its industrial and organizational psychology program.

Houston's University of Texas Health Science Center earned the No. 3 spots in Texas for its masters and doctorate nursing programs, with the programs earning the No. 28 and No. 33 spots overall in the nation.

The University of Houston earned the No. 5 spot in Texas for its graduate education program, and No. 70 nationally. It is the No. 63 best business school and No. 69 best engineering school in the nation, according to the report.

U.S. News publishes its national "Best Graduate Schools" rankings every year, which looks at several programs including business, education, engineering, fine arts, health, and many others. For the 2023-2024 report, the publication decided to withhold its rankings for law and medical schools, which will be published later this year. It also changed the methodology for ranking education and business schools by focusing on outcome rather than a program’s reputation and selectivity.

“When prospective students are considering their options for graduate school, the Best Graduate Schools rankings are designed to help them identify schools that excel in the program they want to study,” said LaMont Jones, senior editor of Education at U.S. News. “With many options available, U.S. News provides a wealth of data in an easy format to help each student make the best decision.”

Some category rankings have not been released for the 2023-24 school year, but the Baylor College of Medicine ranked No. 1 in Texas in the “Best Medical Schools: Research” and “Primary Care” categories for 2022. Additionally, the University of Houston Law Center, South Texas College of Law, and Texas Southern University Marshall School of Law previously ranked No. 3 (tied), No. 6, and No. 8 respectively in Texas for the 2022-2023 academic year.

------

This article originally ran on CultureMap.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”

Chevron enters the lithium market with major Texas land acquisition

to market

Chevron U.S.A., a subsidiary of Houston-based energy company Chevron, has taken its first big step toward establishing a commercial-scale lithium business.

Chevron acquired leaseholds totaling about 125,000 acres in Northeast Texas and southwest Arkansas from TerraVolta Resources and East Texas Natural Resources. The acreage contains a high amount of lithium, which Chevron plans to extract from brines produced from the subsurface.

Lithium-ion batteries are used in an array of technologies, such as smartwatches, e-bikes, pacemakers, and batteries for electric vehicles, according to Chevron. The International Energy Agency estimates lithium demand could grow more than 400 percent by 2040.

“This acquisition represents a strategic investment to support energy manufacturing and expand U.S.-based critical mineral supplies,” Jeff Gustavson, president of Chevron New Energies, said in a news release. “Establishing domestic and resilient lithium supply chains is essential not only to maintaining U.S. energy leadership but also to meeting the growing demand from customers.”

Rania Yacoub, corporate business development manager at Chevron New Energies, said that amid heightening demand, lithium is “one of the world’s most sought-after natural resources.”

“Chevron is looking to help meet that demand and drive U.S. energy competitiveness by sourcing lithium domestically,” Yacoub said.

---

This article originally appeared on EnergyCapital.